<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>Adult naive T cells are able to regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Adult naive T cells are able to regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Adult naive T cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Adult naive T cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Adult naive T cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Adult naive T cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Adult naive T cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Adult naive T cells are observed to regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Adult naive T cells are observed to regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Adult naive T cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Adult naive T cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Adult naive T cells can regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Adult naive T cells can regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Adult naive T cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Adult naive T cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Adult naive T cells have regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Adult naive T cells have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Adult naive T cells have the probability of regaining the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Adult naive T cells have the probability of regaining the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Adult naive T cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Adult naive T cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Adult naive T cells may have regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Adult naive T cells may have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Adult naive T cells regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Adult naive T cells regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Adult naive T cells regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Adult naive T cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Adult naive T cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Adult naive T cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Adult naive T cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Adult naive T cells will regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Adult naive T cells will regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>After androgen withdrawal and antiandrogen treatment, Adult naive T cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Adult naive T cells</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>After androgen withdrawal and antiandrogen treatment, HIV-specific CD4+ T cells of viremic patients will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>After androgen withdrawal and antiandrogen treatment, HSC will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>After androgen withdrawal and antiandrogen treatment, endothelial cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>EBD cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>EBD cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>EBD cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>EBD cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>EBD cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>EBD cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>EBD cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>EBD cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>EBD cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>EBD cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>EBD cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>EBD cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>EBD cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>EBD cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>EBD cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>Further, HSC are able to be found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>Further, HSC are able to be observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>Further, HSC are able to be proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>Further, HSC could be found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Further, HSC could be induced to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Further, HSC could be observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Further, HSC could be proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Further, HSC have been found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Further, HSC have been found to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Further, HSC have been observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Further, HSC have been observed to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Further, HSC have been proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Further, HSC have been proven to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>HIV-specific CD4+ T cells of viremic patients are able to regain the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>HIV-specific CD4+ T cells of viremic patients are able to regain the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>HIV-specific CD4+ T cells of viremic patients are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>HIV-specific CD4+ T cells of viremic patients are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>HIV-specific CD4+ T cells of viremic patients are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>HIV-specific CD4+ T cells of viremic patients are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>HIV-specific CD4+ T cells of viremic patients are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>HIV-specific CD4+ T cells of viremic patients are observed to regain the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>HIV-specific CD4+ T cells of viremic patients are observed to regain the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>HIV-specific CD4+ T cells of viremic patients can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>HIV-specific CD4+ T cells of viremic patients can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>HIV-specific CD4+ T cells of viremic patients can continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>HIV-specific CD4+ T cells of viremic patients can continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>HIV-specific CD4+ T cells of viremic patients can regain the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>HIV-specific CD4+ T cells of viremic patients can regain the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>HIV-specific CD4+ T cells of viremic patients continued to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>HIV-specific CD4+ T cells of viremic patients has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>HIV-specific CD4+ T cells of viremic patients has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>HIV-specific CD4+ T cells of viremic patients has continued to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>HIV-specific CD4+ T cells of viremic patients has continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>HIV-specific CD4+ T cells of viremic patients has the ability to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>HIV-specific CD4+ T cells of viremic patients has the ability to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>HIV-specific CD4+ T cells of viremic patients has the probability of continuing to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>HIV-specific CD4+ T cells of viremic patients has the probability of continuing to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>HIV-specific CD4+ T cells of viremic patients have regained the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>HIV-specific CD4+ T cells of viremic patients have regained the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>HIV-specific CD4+ T cells of viremic patients have the probability of regaining the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>HIV-specific CD4+ T cells of viremic patients have the probability of regaining the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>HIV-specific CD4+ T cells of viremic patients is able to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>HIV-specific CD4+ T cells of viremic patients is able to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>HIV-specific CD4+ T cells of viremic patients may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>HIV-specific CD4+ T cells of viremic patients may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>HIV-specific CD4+ T cells of viremic patients may have continued to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>HIV-specific CD4+ T cells of viremic patients may have continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>HIV-specific CD4+ T cells of viremic patients may have regained the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>HIV-specific CD4+ T cells of viremic patients may have regained the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>HIV-specific CD4+ T cells of viremic patients regain the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>HIV-specific CD4+ T cells of viremic patients regained the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>HIV-specific CD4+ T cells of viremic patients regained the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>HIV-specific CD4+ T cells of viremic patients was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>HIV-specific CD4+ T cells of viremic patients was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>HIV-specific CD4+ T cells of viremic patients wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>HIV-specific CD4+ T cells of viremic patients wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>HIV-specific CD4+ T cells of viremic patients will continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>HIV-specific CD4+ T cells of viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>HIV-specific CD4+ T cells of viremic patients will regain the ability to proliferate indefinitely when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>HIV-specific CD4+ T cells of viremic patients will regain the ability to proliferate when costimulation was provided by anti-CD28 antibody (Figure 6B).</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, are able to proliferate strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, are able to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, are observed to proliferate strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, are observed to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, can proliferate strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, can proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, can strongly proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, could have proliferated strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, could have proliferated when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, could have strongly proliferated when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, have proliferated when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, have strongly proliferated when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, have the ability to proliferate strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, have the ability to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, may proliferate strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, may proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, may strongly proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, might have proliferated strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, might have proliferated when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, might have strongly proliferated when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, proliferate strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, proliferated strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, proliferated when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, will proliferate strongly when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, will proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>HIV-specific CD4+ T cells of viremic patients, which are at rest in normal conditions, will strongly proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>HSC are able to regain the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>HSC are able to regain the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>HSC are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>HSC are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>HSC are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>HSC are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>HSC are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>HSC are observed to regain the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>HSC are observed to regain the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>HSC can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>HSC can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>HSC can regain the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>HSC can regain the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>HSC has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>HSC has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>HSC have regained the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>HSC have regained the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>HSC have the probability of regaining the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>HSC have the probability of regaining the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>HSC may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>HSC may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>HSC may have regained the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>HSC may have regained the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>HSC regain the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>HSC regained the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>HSC regained the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>HSC was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>HSC was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>HSC wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>HSC wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">HSC</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>HSC will regain the ability to proliferate indefinitely through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>HSC will regain the ability to proliferate through 8 days of G-CSF treatment (Figure 6B).</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>HSC, which are at rest in normal conditions, are able to proliferate strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>HSC, which are at rest in normal conditions, are able to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>HSC, which are at rest in normal conditions, are observed to proliferate strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>HSC, which are at rest in normal conditions, are observed to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>HSC, which are at rest in normal conditions, can proliferate strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>HSC, which are at rest in normal conditions, can proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>HSC, which are at rest in normal conditions, can strongly proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>HSC, which are at rest in normal conditions, could have proliferated strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>HSC, which are at rest in normal conditions, could have proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>HSC, which are at rest in normal conditions, could have strongly proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>HSC, which are at rest in normal conditions, have proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>HSC, which are at rest in normal conditions, have strongly proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>HSC, which are at rest in normal conditions, have the ability to proliferate strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>HSC, which are at rest in normal conditions, have the ability to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>HSC, which are at rest in normal conditions, may proliferate strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>HSC, which are at rest in normal conditions, may proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>HSC, which are at rest in normal conditions, may strongly proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>HSC, which are at rest in normal conditions, might have proliferated strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>HSC, which are at rest in normal conditions, might have proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>HSC, which are at rest in normal conditions, might have strongly proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>HSC, which are at rest in normal conditions, proliferate strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>HSC, which are at rest in normal conditions, proliferated strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>HSC, which are at rest in normal conditions, proliferated through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>HSC, which are at rest in normal conditions, will proliferate strongly through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>HSC, which are at rest in normal conditions, will proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>HSC, which are at rest in normal conditions, will strongly proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>Our observations illustrate that Adult naive T cells can be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>Our observations illustrate that Adult naive T cells can be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Our observations illustrate that Adult naive T cells has been endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Our observations illustrate that Adult naive T cells has been endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Our observations illustrate that Adult naive T cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>Our observations illustrate that Adult naive T cells has the ability to be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>Our observations illustrate that Adult naive T cells is able to be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>Our observations illustrate that Adult naive T cells is able to be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>Our observations illustrate that Adult naive T cells is endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>Our observations illustrate that Adult naive T cells is shown to be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>Our observations illustrate that Adult naive T cells is shown to be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>Our observations illustrate that Adult naive T cells may have been endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>Our observations illustrate that Adult naive T cells may have been endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>Our observations illustrate that Adult naive T cells was endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>Our observations illustrate that Adult naive T cells was endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>Our observations illustrate that Adult naive T cells will be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>Our observations illustrate that Adult naive T cells will be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients can be endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients can be endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients has been endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients has been endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients has the ability to be endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients has the ability to be endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients is able to be endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients is able to be endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients is endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients is shown to be endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients is shown to be endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients may have been endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients may have been endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients was endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients was endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients will be endowed with the biochemical machinery to proliferate indefinitely when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>Our observations illustrate that HIV-specific CD4+ T cells of viremic patients will be endowed with the biochemical machinery to proliferate when costimulation was provided by anti-CD28 antibody, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>Our observations illustrate that HSC can be endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>Our observations illustrate that HSC can be endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>Our observations illustrate that HSC has been endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>Our observations illustrate that HSC has been endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>Our observations illustrate that HSC has the ability to be endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>Our observations illustrate that HSC has the ability to be endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>Our observations illustrate that HSC is able to be endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>Our observations illustrate that HSC is able to be endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>Our observations illustrate that HSC is endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>Our observations illustrate that HSC is shown to be endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>Our observations illustrate that HSC is shown to be endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>Our observations illustrate that HSC may have been endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>Our observations illustrate that HSC may have been endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>Our observations illustrate that HSC was endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>Our observations illustrate that HSC was endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>Our observations illustrate that HSC will be endowed with the biochemical machinery to proliferate indefinitely through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>Our observations illustrate that HSC will be endowed with the biochemical machinery to proliferate through 8 days of G-CSF treatment, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has the ability to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is shown to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is shown to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells may have been endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells may have been endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>Our observations illustrate that endothelial cells can be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>Our observations illustrate that endothelial cells can be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>Our observations illustrate that endothelial cells has been endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>Our observations illustrate that endothelial cells has been endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>Our observations illustrate that endothelial cells is able to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>Our observations illustrate that endothelial cells is able to be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>Our observations illustrate that endothelial cells is endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>Our observations illustrate that endothelial cells is shown to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>Our observations illustrate that endothelial cells is shown to be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>Our observations illustrate that endothelial cells may have been endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>Our observations illustrate that endothelial cells may have been endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>Our observations illustrate that endothelial cells was endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>Our observations illustrate that endothelial cells was endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>Our observations illustrate that endothelial cells will be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>Our observations illustrate that endothelial cells will be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>Stat5ab-/-peripheral T cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>Stat5ab-/-peripheral T cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>Stat5ab-/-peripheral T cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>Stat5ab-/-peripheral T cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>Stat5ab-/-peripheral T cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>Stat5ab-/-peripheral T cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>Stat5ab-/-peripheral T cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>Stat5ab-/-peripheral T cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>Stat5ab-/-peripheral T cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>Stat5ab-/-peripheral T cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>Stat5ab-/-peripheral T cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>Stat5ab-/-peripheral T cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>Stat5ab-/-peripheral T cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>Stat5ab-/-peripheral T cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>Stat5ab-/-peripheral T cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are able to proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are able to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, can proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, can proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, can strongly proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may strongly proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, might have proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, might have proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, might have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will strongly proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>Treatment of HIV-specific CD4+ T cells of viremic patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when costimulation was provided by anti-CD28 antibody.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>Treatment of HSC of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate through 8 days of G-CSF treatment.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>endothelial cells are able to regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>endothelial cells are able to regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>endothelial cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>endothelial cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>endothelial cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>endothelial cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>endothelial cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>endothelial cells are observed to regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>endothelial cells are observed to regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>endothelial cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>endothelial cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>endothelial cells can regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>endothelial cells can regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>endothelial cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>endothelial cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>endothelial cells have regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>endothelial cells have regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>endothelial cells have the probability of regaining the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>endothelial cells have the probability of regaining the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>endothelial cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>endothelial cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>endothelial cells may have regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>endothelial cells may have regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>endothelial cells regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>endothelial cells regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>endothelial cells regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>endothelial cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>endothelial cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>endothelial cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>endothelial cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>endothelial cells will regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>endothelial cells will regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>endothelial cells, which are at rest in normal conditions, are able to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>endothelial cells, which are at rest in normal conditions, are able to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>endothelial cells, which are at rest in normal conditions, are observed to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>endothelial cells, which are at rest in normal conditions, are observed to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>endothelial cells, which are at rest in normal conditions, can proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>endothelial cells, which are at rest in normal conditions, can proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>endothelial cells, which are at rest in normal conditions, can strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>endothelial cells, which are at rest in normal conditions, could have proliferated strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>endothelial cells, which are at rest in normal conditions, could have proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>endothelial cells, which are at rest in normal conditions, could have strongly proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>endothelial cells, which are at rest in normal conditions, have proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>endothelial cells, which are at rest in normal conditions, have strongly proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>endothelial cells, which are at rest in normal conditions, have the ability to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>endothelial cells, which are at rest in normal conditions, have the ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>endothelial cells, which are at rest in normal conditions, may proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>endothelial cells, which are at rest in normal conditions, may proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>endothelial cells, which are at rest in normal conditions, may strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>endothelial cells, which are at rest in normal conditions, might have proliferated strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>endothelial cells, which are at rest in normal conditions, might have proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>endothelial cells, which are at rest in normal conditions, might have strongly proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>endothelial cells, which are at rest in normal conditions, proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>endothelial cells, which are at rest in normal conditions, proliferated strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>endothelial cells, which are at rest in normal conditions, proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>endothelial cells, which are at rest in normal conditions, will proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>endothelial cells, which are at rest in normal conditions, will proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>endothelial cells, which are at rest in normal conditions, will strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>the androgen responsive prostate cancer cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>the androgen responsive prostate cancer cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>the androgen responsive prostate cancer cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>the androgen responsive prostate cancer cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>the androgen responsive prostate cancer cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>the androgen responsive prostate cancer cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>the androgen responsive prostate cancer cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>the androgen responsive prostate cancer cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>the androgen responsive prostate cancer cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>the androgen responsive prostate cancer cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>the androgen responsive prostate cancer cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>the androgen responsive prostate cancer cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>the androgen responsive prostate cancer cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>the androgen responsive prostate cancer cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>the androgen responsive prostate cancer cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>the human placenta are able to regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>the human placenta are able to regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>the human placenta are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>the human placenta are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>the human placenta are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>the human placenta are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>the human placenta are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>the human placenta are observed to regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>the human placenta are observed to regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>the human placenta can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>the human placenta can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>the human placenta can regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>the human placenta can regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>the human placenta has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>the human placenta has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>the human placenta have regained the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>the human placenta have regained the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>the human placenta have the probability of regaining the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>the human placenta have the probability of regaining the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>the human placenta may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>the human placenta may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>the human placenta may have regained the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>the human placenta may have regained the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>the human placenta regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>the human placenta regained the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>the human placenta regained the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>the human placenta was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>the human placenta was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>the human placenta wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>the human placenta wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>the human placenta will regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>the human placenta will regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>the human placenta, which are at rest in normal conditions, are able to proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>the human placenta, which are at rest in normal conditions, are able to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>the human placenta, which are at rest in normal conditions, can proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>the human placenta, which are at rest in normal conditions, can proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>the human placenta, which are at rest in normal conditions, can strongly proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>the human placenta, which are at rest in normal conditions, could have proliferated strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>the human placenta, which are at rest in normal conditions, could have proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>the human placenta, which are at rest in normal conditions, could have strongly proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>the human placenta, which are at rest in normal conditions, have proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>the human placenta, which are at rest in normal conditions, have strongly proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>the human placenta, which are at rest in normal conditions, may proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>the human placenta, which are at rest in normal conditions, may proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>the human placenta, which are at rest in normal conditions, may strongly proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>the human placenta, which are at rest in normal conditions, might have proliferated strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>the human placenta, which are at rest in normal conditions, might have proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>the human placenta, which are at rest in normal conditions, might have strongly proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>the human placenta, which are at rest in normal conditions, proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>the human placenta, which are at rest in normal conditions, proliferated strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>the human placenta, which are at rest in normal conditions, proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>the human placenta, which are at rest in normal conditions, will strongly proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>intrasplenically transplanted fetal liver cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>intrasplenically transplanted fetal liver cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>intrasplenically transplanted fetal liver cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>intrasplenically transplanted fetal liver cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>intrasplenically transplanted fetal liver cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>intrasplenically transplanted fetal liver cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>intrasplenically transplanted fetal liver cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>intrasplenically transplanted fetal liver cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>intrasplenically transplanted fetal liver cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>intrasplenically transplanted fetal liver cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>intrasplenically transplanted fetal liver cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>intrasplenically transplanted fetal liver cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>intrasplenically transplanted fetal liver cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
